Chinmay Jani

This morning, I had the honor of presenting my first Rapid Oral at #ASCO25 🎤 — a truly unforgettable experience ✨. Our study highlights the rising burden of #alcohol-associated cancers 🍷🎗️ across sites, age groups, and sexes @GlopesMd @Latinamd . Grateful to all my mentors @SylvesterCancer team for supporting me at the presentation! @PeterHoseinMD @COlazagasti @Kyle__Edwards @HemOncMiami @SamuelKareffMD

I'm excited to be co-hosting ASCO discussions on Roon, a physicians-only social platform where I'll be sharing updates, takeaways, and discussion in real time throughout the conference. Whether you're attending the conference or following from home, come join us! Link: tinyurl.com/3hwuae6n @ASCO #ASCO26 @SylvesterCancer @OncoAlert @OncBrothers @Latinamd @OpenMedicineHQ

Here are my own #ASCO26 Top 10 🫁 Lung Cancer Abstracts based on potential clinical impact — although there is so much exciting and innovative science being presented across the field. Looking forward to the discussions, debates, and future directions these data may inspire. #LungCancer

Introducing my original #ASCO26 thoracic oncology abstract database! All key lung cancer & thoracic abstracts curated, structured, and searchable in one place. Built to make this year's data faster to navigate, compare, and revisit 🫁🧬 scratch-work-2af.notion.site/36701481075080… @ASCO @OncoAlert @Larvol #LCSM

We built OncoSphere AI: an agentic AI system designed for real multidisciplinary oncology workflows. Not a chatbot. Not a summarizer. An autonomous agent that reasons across guidelines, trial data, imaging, and pathology to support clinical decision-making the way a tumor board actually works. Presenting at #ASCO26 @ASCO: asco.org/abstracts-pres… The oncology AI tools that will matter aren't the ones that answer questions. They're the ones that run workflows navigation, trial matching, treatment sequencing, toxicity guidance, end to end. That's what agentic AI means. That's what we're building!

Incredibly proud of our Chief Fellow Dr. Chinmay Jani, recipient of the 2026 Sylvester Outstanding Clinical Early-Stage Researcher of the Year! 🏆 A testament to his dedication to patients and to advancing cancer research. @Jani_Chinmay @SylvesterCancer @umiamimedicine

Bottom line: judge MCED by the evidence, not the testimonial. Implementation data answer "will clinics adopt it?"; only NHS-Galleri answers "does it help?" Both matter — but don't let a 7/7 accuracy headline from an uncontrolled series stand next to a 142,000-pt randomized trial. Different questions, different weight.

The line that ties all three together: none of the screen-detected cancers had a USPSTF A/B pathway. That's the real MCED thesis — finding lethal cancers with no other screening route. NHS-Galleri tests whether that changes outcomes at population scale. The case series just shows people will use it.

What it legitimately CAN teach: implementation. 69.6% of eligible pts took ≥2 tests, mostly annual; repeat-testing after inconclusive workup behaved sensibly (4/5 cleared on neg retest). Adoption & longitudinal uptake in primary care is exactly what a real-world series should contribute.

What the real world evidence abstracts CAN'T tell you: The private practice experience (10532) is single-arm, n=1,949, 20 signal-positives. "100% CSO accuracy" is 7/7 — CIs near-uninformative. With no control & no capture of cancers among the ~1,925 who tested negative, it structurally can't report sensitivity, specificity, or false-positive burden.

3/ Middle rung: PATHFINDER 2 (LBA10509) — registrational, intended-use safety & performance. The dataset built to support regulatory approval. Then the bottom rung, and the one to read carefully: Sue et al (Abstr 10532), a single private-practice network's implementation experience.

2/ Top rung: NHS-Galleri (LBA100, Swanton et al) — the first & only RCT of an MCED test, 142,000+ participants. Feb press release: substantial drop in stage IV diagnoses, more stage I/II detection, ~4x cancer detection rate. The honest asterisk: higher-than-expected stage III incidence. Mortality data still maturing.

MCED testing is having its moment at #ASCO26, and it's a useful lesson in the evidence ladder. Three abstracts, three very different rungs — and they shouldn't be read as equivalent. 🧵 @OncoAlert @OncBrothers @StephenVLiu @Jani_Chinmay @asco @myESMO @glopesmd @SylvesterCancer @latinamd @iaslc @COlazagasti

One more Real-world #ASCO26 data (Ghosh et al, Mayo): enterprise-wide MCED (Galleri) testing across 3 sites, 7,300 pts. PPV 58.7% (32/57 positives) — believable precisely because it's denominator-anchored, not a small-n 100%. But the quiet stat matters most: 5.2% of test-NEGATIVE pts still got a cancer dx. A negative is not an all-clear. #LCSM @OncoAlert @OncBrothers @StephenVLiu @Jani_Chinmay @asco @myESMO @glopesmd @SylvesterCancer @latinamd @iaslc @COlazagasti

Honored to join the @sitcancer Asia Special Interest Group (SIG) focused on expanding global access to immuno-oncology and fostering international collaboration 🌍🎗️ Looking forward to contributing and learning through this initiative. 🤝 #SITC #GlobalOncology #Immunotherapy @SylvesterCancer @umiamimedicine @GlopesMd @Latinamd @HemOncMiami

Important #ASCO26 first look (Abstract 8516): TSN1611, an oral KRAS G12D inhibitor — the common, long-"undruggable" KRAS variant with no approved drug (vouchers excluded). In pretreated G12D+ NSCLC, ORR 50%, DCR 90%, with intracranial responses. Strikingly clean: only 9.4% gr 3 TRAEs, zero discontinuations. G12D finally yielding. Worth watching. #LCSM @OncoAlert @OncBrothers @StephenVLiu @Jani_Chinmay @asco @myESMO @glopesmd @SylvesterCancer @latinamd @iaslc @COlazagasti

Notable #ASCO26 data (Abstract 8503, ALKOVE-1): neladalkib, a next-gen ALK TKI built to beat resistance, shows real activity AFTER lorlatinib — ORR 26% post-lorla, 48% after a single 2nd-gen TKI, with CNS responses & activity vs G1202R. TKI-naïve ORR 86%. A genuine post-lorlatinib option emerging. #LCSM @OncoAlert @OncBrothers @StephenVLiu @Jani_Chinmay @asco @myESMO @glopesmd @SylvesterCancer @latinamd @iaslc @COlazagasti

Ab#4507 @ASCO #ASCO26 by @tompowles1 @shilpaonc👉bit.ly/4nJjvw7👉3.5 yr f/u of Ph3 EV-302 in aUC #bladdercancer👉42-month OS rate, 44% vs 24.6%; HR=0.53👉among pts w/ CR, 66% had initially PR👇 @OncoAlert @urotoday @uromigos @BladderCancerUS

This is one is personal as I presented the five-year follow-up of ARROS last year: Phase 3 confirmation at #ASCO26 (Abstract 8504, AcceleRET-Lung): 1L pralsetinib doubles PFS vs chemo in RET+ NSCLC (18.7 vs 9.0 mo, p=0.003), ORR 66% vs 42%, DOR 20.6 vs 9.7 mo. RET-directed 1L therapy validated in a randomized trial. Infection signal? (pneumonia 19% vs 6%). #LCSM @OncoAlert @OncBrothers @StephenVLiu @Jani_Chinmay @asco @myESMO @glopesmd @SylvesterCancer @latinamd @iaslc @COlazagasti

Encouraging #ASCO26 data (Abstract 8510, Krascendo-170): chemo-free 1L divarasib (KRAS G12Ci) + pembro in KRAS G12C+ NSCLC — ORR 73%, mPFS 19.3 mo, no PD as best response. Works even in PD-L1–negative tumors (ORR 70%). A chemo-free 1L KRAS option taking shape. Watch the hepatotox (gr 3/4 ALT 20%). But is it better than Chemo IO here? #LCSM @OncoAlert @OncBrothers @StephenVLiu @Jani_Chinmay @asco @myESMO @glopesmd @SylvesterCancer @latinamd @iaslc @COlazagasti

Provocative #ASCO26 data (Abstract 8509, NEOVADE): neoadjuvant almonertinib → chemo-IO in resectable EGFR+ NSCLC, testing the "TKI makes the tumor hot" idea. MPR 40.6%, pCR 15.6% overall — but it's all PD-L1–driven: pCR 33% if PD-L1≥1%, 0% if <1%. Sequencing IO into EGFR+ may only work where PD-L1 is up. Back to the future with IO in EGFR? #LCSM @OncoAlert @OncBrothers @StephenVLiu @Jani_Chinmay @asco @myESMO @glopesmd @SylvesterCancer @latinamd @iaslc @COlazagasti